MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric disorders. VANCOUVER, BC, Oct. 7, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce the formation of its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary…
